Figure 2

The effect of a neutralizing monoclonal antibody and of VEGF receptor-specific ligands on Primary Human Osteoblast alkaline phosphatase release in vitro. Bone nodule formation was assessed by von Kossa staining and alkaline phosphatase release by p-nitrophenyl phosphate hydrolysis as described in Materials and Methods. mAB: neutralizing monoclonal antibody to VEGF 165 (0.3 ug/mL), VEGF 165: vascular endothelial growth factor isotype 165, PlGF: placental like growth factor. Data illustrates mean +/- standard error of the mean in each case. The results were derived from six separate experiments, with triplicates performed in each experiment. # p < 0.05 represents statistically significant differences compared to control, * p < 0.05 represents statistically significant differences compared to VEGF 165.